Publication
Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.
Orazio Caffo, Ugo De Giorgi, Francesco Ferraú, Maddalena Donini, Gaetano Facchini, Marco Maruzzo, Marcello Tucci, Vincenza Conteduca, Francesca Maines, Lorena Rossi, Antonello Veccia, Enzo Galligioni
Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2016.34.2_suppl.326